Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $23,493 - $35,055
12,300 New
12,300 $0
Q2 2022

Aug 12, 2022

SELL
$1.98 - $3.17 $19,800 - $31,700
-10,000 Reduced 34.6%
18,900 $3,000
Q1 2022

May 12, 2022

SELL
$2.42 - $3.98 $92,928 - $152,832
-38,400 Reduced 57.06%
28,900 $13,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $121,601 - $180,251
39,100 Added 138.65%
67,300 $35,000
Q3 2021

Nov 10, 2021

BUY
$2.65 - $4.62 $27,560 - $48,048
10,400 Added 58.43%
28,200 $27,000
Q2 2021

Aug 11, 2021

BUY
$2.5 - $3.51 $8,750 - $12,285
3,500 Added 24.48%
17,800 $7,000
Q1 2021

May 14, 2021

SELL
$3.14 - $4.84 $36,424 - $56,144
-11,600 Reduced 44.79%
14,300 $8,000
Q4 2020

Feb 16, 2021

BUY
$2.76 - $4.97 $31,739 - $57,155
11,500 Added 79.86%
25,900 $12,000
Q3 2020

Nov 13, 2020

BUY
$1.75 - $6.2 $25,200 - $89,280
14,400 New
14,400 $8,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.